Table 1.
Clinicopathological characteristics of clinical cohort
| No. of patients N = 102 |
|
|---|---|
| Median age, years (range) | 64 (30–82) |
| Sex (male/female), n (%) | 64 (62.7)/38 (37.2) |
| Tumor location (Ra/Rb/P), n (%) | 18 (17.6)/82 (80.4)/2 (2.0) |
| Distance from anal verge, cm (range) | 4.0 (0–12.0) |
| CEA level, ng/mL (range) | 3.95 (0.8–82.3) |
| CA19-9 level, U/mL (range) | 11.5 (1–1823) |
| Lateral lymph node dissection, n (%) | 69 (67.6) |
| Median tumor size, mm (range) | 44 (5–130) |
| cT status, n (%) | |
| cT1b/cT2/cT3/cT4 | 7 (6.9)/17 (16.7)/54 (52.9)/24 (23.5) |
| cN status (proximal lymph node area), n (%) | |
| cN0/cN1/cN2 | 30 (29.4)/52 (51.0)/20 (19.6) |
| Clinical lateral lymph node status, n (%) | |
| cLLN positive/cLLN negative | 26 (25.5)/76 (74.5) |
| Distant metastasis, n (%) | |
| cM0/cM1 | 91 (89.2)/11 (10.8) |
| Neoadjuvant chemotherapy, n (%) | |
| Yes/no | 21 (20.6)/81 (79.4) |
| Median postoperative period, months (range) | 49.1 (3.8–121.9) |
| (y)pT status, n (%) | |
| (y)pT0/(y)pT1b/(y)pT2/(y)pT3/(y)pT4 | 1 (1.0)/7 (6.9)/24 (23.5)/56 (54.9)/14 (13.7) |
| Proximal lymph node metastasis, n (%) | |
| (y)pN0/(y)pN1/(y)pN2 | 43 (42.2)/29 (28.4)/30 (29.4) |
| Lateral lymph node metastasis, n (%) | 16 (15.7) |
| Right side/left side | 13 (12.7)/7 (6.9) |
| Lymphatic invasion, n (%) | |
| Positive/negative | 84 (82.4)/18 (17.6) |
| Venous invasion, n (%) | |
| Positive/negative | 78 (76.5)/24 (23.5) |
| Histopathological grade, n (%) | |
| G1/G2/G3 | 32 (31.4)/55 (53.9)/15 (14.7) |
| Tumor resection margin, n (%) | |
| R0/R1 | 93 (91.2)/9 (8.8) |
| Lateral lymph node recurrence, n (%) | |
| Present/absent | 4 (3.9)/98 (96.1) |
LLN lateral lymph node, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9